Immunomedics, Inc. (IMMU) Reports Development of a New Labeling Kit for Attaching Fluorine-18 to Peptides and Temperature-Sensitive Biomolecules, Including Antibodies  
6/12/2012 10:12:24 AM

MIAMI BEACH, Fla., June 11, 2012 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced the development of a lyophilized kit for the rapid and facile labeling of peptides with fluorine-18 (18F) with good yields and high specific activity.